Danilo Perrotti, MD, PhD
Assistant Professor
Molecular Virology, Immunology & Medical Genetics

860 Biomedical Research Tower

460 W. 12th St

Columbus, OH 43210
Phone: (614) 293-5739
Fax: (614) 293-5952
Danilo.Perrotti@osumc.edu

Danilo Perrotti Curriculum Vitae

Research Interests
Molecular Biology and Cancer Genetics (MBCG) Program 
 
Select Publications
Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox.  Perrotti D, Marcucci G, Caligiuri MA. J Clin Oncol 22(4): 582-284, 2004.

The biology of CML blast crisis. Perrotti D. Blood in press: 2004.

Altered mRNA translation: possible mechanism for CML disease progression Perrotti D. Cell Cycle 2(3): 177-180, 2003.

The transcription activation function of C/EBP alpha is required for induction of granulocytic differentiation Perrotti D. Blood in press: 2003. 

Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Marcucci G, Perrotti D, Caligiuri MA. Clin Cancer Res 9(4): 1248-1252, 2003.

Perrotti D^#, Cesi V, Trotta R., Guerzoni C, Santilli G., Campbell K., Iervolino A., Condorelli F., Gambacorti-Passerini C, Caligiuri MA. and B. Calabretta. BCR/ABL suppresses C/EBP? expression through the translation inhibitory activity of the hnRNP E2. Nature Genetics, 30: 48-58, 2002                (^#): co-corresponding author

Iervolino A., G. Santilli, R. Trotta, C. Guerzoni, V. Cesi, A. Bergamaschi, C. Gambacorti-Passerini, B. Calabretta, and D. Perrotti. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol. Cell. Biol. 22:2255-66, 2002.

Trotta, R., T. Vignudelli, O. Candini, R. V. Intine, L. Pecorari, C. Guerzoni, G. Santilli, M.W. Byrom, S. Goldoni, L.P. Ford, M. A. Caligiuri, R.J. Maraia, D. Perrotti*, and B. Calabretta. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell, 3:145-60.2003                  (*): co-Corresponding Author.

Perrotti D* and Calabretta B. Translational Regulation by the p210 BCR/ABL Oncoprotein. Oncogene, 23(18):3222-9, 2004      (*): Corresponding Author.

Calabretta B and Perrotti D. The Biology of CML Blast Crisis. Blood, 103(11):4010-22, 2004.

Perrotti D*., Turturro F. and Neviani P. BCR/ABL, mRNA Translation and Apoptosis. Cell Death Differ. 2005, 6:534-40.                                                                                  (*): Corresponding Author.

Neviani P., Santhanam R., Trotta R., Notari M., Blaser B.W., Liu S., Mao H, Chang JS, Galietta A, Uttam A, Roy D.C., Valtieri M., Bruner-Klisovic R., Caligiuri M.A., Bloomfield C.D., Marcucci G., and D. Perrotti.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell.;8:355-68, 2005

Notari M., Neviani P., Santhanam R., Galietta A, Chang JS., Blaser B.W., Willis A.E., Roy D.C., Caligiuri M.A., Marcucci G. and D. Perrotti. A MAPK/hnRNP K pathway controls BCR/ABL oncogenic potential by regulating c-myc mRNA translation. Blood,107:2507-16, 2006

Perrotti D. and Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br. J. Cancer, 95:775-81, 2006

Perrotti D. and Neviani P. From mRNA metabolism to Cancer therapy: CML shows the way. Clin. Cancer Res. 13(6):1638-42, 2007

Chang JS., Santhanam R., Trotta R., Neviani P., Eiring A., Briercheck E., Ronchetti M., Roy DC., Calabretta B., Caligiuri MA and D. Perrotti.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP E2-dependent suppression of C/EBP?-driven Myeloid Differentiation. . Blood. 2007 May 2; [Epub ahead of print]

Neviani P., Santhanam R., Oaks J., Eiring A., Notari M., Blaser BW., Liu S., Trotta R., Muthusamy N., Verrills, N., Gambacorti-Passerini C., Druker BJ., Cortes J., Marcucci G., Chen CS, Roy DC., Caligiuri MA., Bloomfield CD.,  Byrd J and D. Perrotti. FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL. J Clin.  Invest.  September  2007.